|
|
|
|
|
HONG KONG, July 21, 2020 - (ACN Newswire) - Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing oncology and autoimmune therapeutics, announced that the new drug application (NDA) for Geptanolimab, a novel PD-1 mAb drug candidate, has been accepted by the National Medical Products Administration ("NMPA") for the treatment of Peripheral T cell Lymphoma (PTCL).
On the same day, Genor Biopharma announced the appointment of Mr. CHEN Wende as Chief Operation Officer. In this role, Mr. CHEN will oversee commercialization and prepare for launches of late-stage drug candidates.
Mr. CHEN brings over 20 years of experience in biopharmaceutical industry, focusing on sales and marketing and business operation at Roche, AstraZeneca, and Pfizer in China. Mr. CHEN was most recently Chief Commercial Officer at a well-known biotech company. Before that, Mr. CHEN served as Vice President at Roche China, overseeing Corporate Affairs, Market Access and Channel Management for a number of key drugs including Herceptin, MabThera, Avastin, Tarceva and Zelboraf. Mr. CHEN also served as Senior Vice President at AstraZeneca from 2010 and as Senior Sales Director at Pfizer from 2000.
"We are excited to appoint Mr. CHEN as COO of Genor Biopharma. We are looking to file NDAs for a number of our late-stage drug candidates in the near term," commented Dr. GUO, Chief Executive Officer of Genor Biopharma, "With over 20 years of experience in drug commercialization and deep insight of the landscape, Mr. CHEN will build our in-house commercialization team and lead our drug launches with differentiated strategy and drive our transformation into a biopharma company."
About JHBP (CY) Holdings Limited ("Genor Biopharma")
Established in December 2007, JHBP (CY) Holdings Limited is a biopharmaceutical powerhouse focusing on developing and commercializing oncology and autoimmune drugs. The Company has been strategically focused on major therapeutic areas with substantial unmet medical needs. At present, the Company has more than 10 drug candidates, 10 of which have entered the clinical development stage. The Company's pipeline products are mainly deployed in the field of cancer and other major diseases and have established a series of mature technology platforms in antibody drug research, development and manufacturing to serve patients in China and around the world. The Company's leadership team boasts more than 20 years of industry experience in global biopharmaceutical companies such as Pfizer, Merck, Amgen and AbbVie with proven track record and a well-balanced combination of expertise. The Company currently has around 400 employees across 3 sites in China - Shanghai Zhangjiang, Yunnan Yuxi, and Beijing office, as well as lab in South San Francisco, US, among which 80% are R&D and clinical specialists.
Topic: Press release summary
Source: Genor Biopharma
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Sensiba Names Monic Ramirez as Managing Partner Amid Firm-Wide Transformation
May 2, 2026 09:00 HKT/SGT
|
|
|
Indonesia's ITS Develops Scalable, High-Efficiency Palm-Based Biogasoline Production Technology 
May 2, 2026 04:00 HKT/SGT
|
|
|
LemonBottle Concludes FACE & BODY 2026, Secures Latin America Foothold
May 1, 2026 23:00 HKT/SGT
|
|
|
Global Experts call for Paradigm Shift in Medicine, Health and Education to Save Lives and Fight Escalating Health Crisis
May 1, 2026 21:30 HKT/SGT
|
|
|
Formerra Appoints Matt Borowiec as Chief Commercial Officer
May 1, 2026 21:00 HKT/SGT
|
|
|
Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions
May 1, 2026 20:00 HKT/SGT
|
|
|
6 Factors to Consider Before Choosing a Credit Card That Matches Your Lifestyle
May 1, 2026 14:00 HKT/SGT
|
|
|
Representatives from More Than 40 Countries Discuss New Models of Global Growth in Moscow
May 1, 2026 12:30 HKT/SGT
|
|
|
Global Leaders Converge in Bangkok for the 18th Annual Global CSR & ESG Summit & Awards 2026
May 1, 2026 10:10 HKT/SGT
|
|
|
ULVAC Establishes Japan-Based Production for Rare-Earth Magnet Vacuum Melting Furnaces
Friday, May 1, 2026 10:00:00 AM
|
|
|
|
|
More Press release >> |
|
 |
|
|
|
|
 |
|
